Discovery of PF-06855800, a SAM competitive PRMT5 inhibitor with potent antitumor activity

被引：4

作者：

Mcalpine, Indrawan J. ^{[1
]}

Tatlock, John ^{[1
]}

Billitti, Joseph ^{[1
]}

Braganza, John ^{[1
]}

Brooun, Alexei ^{[1
]}

Deng Ya-Li ^{[1
]}

Hirakawa, Brad ^{[1
]}

Jensen-Pergakes, Kristen ^{[1
]}

Kumpf, Robert ^{[1
]}

Liu, Wei ^{[1
]}

Maegley, Karen ^{[1
]}

McTigue, Michele ^{[1
]}

Patman, Ryan ^{[1
]}

Rui, Eugene ^{[1
]}

Scales, Stephanie ^{[1
]}

Spiegel, Noah ^{[1
]}

Tran-Dube, Michelle ^{[1
]}

Wang, Fen ^{[1
]}

Wang, Zhenxiong ^{[1
]}

Yamazaki, Shinji ^{[1
]}

Zhang, Tao ^{[1
]}

Wythes, Martin ^{[1
]}

机构：

[1] Pfizer Global R&D, San Diego, CA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-4857

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4857

引用

页数：2

共 50 条

[41] The discovery and preclinical characterization of AMG 193, a first-in-class MTA-cooperative PRMT5 inhibitor with broad activity against MTAP-null cancers
Bojko-Matuszek, Agnieszka
Kolakowski, Damian
Bojko, Magdalena
Sowinska, Aleksandra
Mitula, Filip
Lacek, Krzysztof
Popiel, Delfina
Kwiatkowski, Sebastian
Kornatowski, Tomasz
Kliszcz, Beata
Jablonska, Anna
Flis, Krzysztof
Wiernicki, Bartosz
Wieczorek, Maciej
Pieczykolan, Jerzy
Abramczyk, Olga
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[42] Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor
Liang, Jianglin Colin
Li, Hongming
Cottrell, Kevin M.
Liu, Yong
Maxwell, John P.
Xin, Zhengyang
Anzalone, Luigi
Ronn, Magnus
Palmieri Jr, Michael A.
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2025, 29 (03) : 946 - 952
[43] Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers
Zhang, W.
Gong, S.
Cottrell, K.
Briggs, K.
Tonini, M.
Gu, L.
Whittington, D.
Yuan, H.
Gotur, D.
Jahic, H.
Huang, A.
Maxwell, J.
Mallender, W.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S26 - S26
[44] MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors
Chen, Si
Hou, Jiakai
Jaffery, Roshni
Guerrero, Ashley
Fu, Rongjie
Shi, Leilei
Zheng, Ningbo
Bohat, Ritu
Egan, Nicholas A.
Yu, Chengtai
Sharif, Sana
Lu, Yue
He, Wei
Wang, Shuyue
Gjuka, Donjeta
Stone, Everett M.
Shah, Pooja Anil
Ahnert, Jordi Rodon
Chen, Taiping
Liu, Xinli
Bedford, Mark T.
Xu, Han
Peng, Weiyi
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
[45] Discovery of NTX-001, a potent Cbl-b inhibitor with antitumor activity in syngeneic models
Csibi-Levin, Fred
Leit, Silvana
Laughton, David L.
Baker, Tom
Jacques, Suzanne L.
Browning, Beth
Toms, Angela V.
Garside, Samantha
D'Archivio, Simon
Kopycka, Katarzyna
Zhu, Xiaohua
Jordan, Allan M.
Thomson, Stuart
Loh, Christine
Tummino, Peter
Ciccone, David N.
CANCER RESEARCH, 2022, 82 (12)
[46] MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models
Smith, Christopher R.
Engstrom, Lars D.
Kulyk, Svitlana
Aranda, Ruth
Waters, Laura
Moya, Krystal
Bowcut, Victoria
Hebbert, Allan
Trinh, David
Briere, David M.
Lawson, J. David
Clarine, Jeff
Rahbaek, Lisa
Christensen, James G.
Marx, Matthew A.
Olson, Peter
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[47] From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
Sarvary, Ian
Vestergaard, Mikkel
Moretti, Loris
Andersson, Jan
Cadahia, Jorge Peiro
Cowland, Sanne
Flagstad, Thomas
Franch, Thomas
Gouliaev, Alex
Husemoen, Gitte
Jacso, Tomas
Kronborg, Titi
Kuropatnicka, Aleksandra
Nadali, Anna
Madsen, Mads
Nielsen, Soren
Pii, David
Ryborg, Soren
Soede, Camillia
Allen, Jennifer R.
Bourbeau, Matthew
Li, Kexue
Liu, Qingyian
Lo, Mei-Chu
Madoux, Franck
Mardirossian, Narbe
Moriguchi, Jodi
Ngo, Rachel
Peng, Chi-Chi
Pettus, Liping
Tamayo, Nuria
Wang, Paul
Kapoor, Rajiv
Belmontes, Brian
Caenepeel, Sean
Hughes, Paul
Liu, Siyuan
Slemmons, Katherine K.
Yang, Yajing
Xie, Fang
Ghimire-Rijal, Sudipa
Mukund, Susmith
Glad, Sanne
JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (06) : 6534 - 6557
[48] PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor
Guo, Cen
Liao, Kai H.
Li, Meng
Wang, I-Ming
Shaik, Naveed
Yin, Donghua
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1619 - 1625
[49] PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Yuan, Jing
Mehta, Pramod P.
Yin, Min-Jean
Sun, Shaoxian
Zou, Aihua
Chen, Jeffrey
Rafidi, Kristina
Feng, Zheng
Nickel, Jeffrey
Engebretsen, Jon
Hallin, Jill
Blasina, Alessandra
Zhang, Eric
Nguyen, Leslie
Sun, Minghao
Vogt, Peter K.
McHarg, Aileen
Cheng, Hengmiao
Christensen, James G.
Kan, Julie L. C.
Bagrodia, Shubha
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2189 - 2199
[50] The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
Garbett, D.
Rao, A. A.
Fischer, M. M.
Belmontes, B.
Slemmons, K.
Appel, M. J.
Fang, Z.
Choy, R.
Tyler, S. R.
Vivian, J.
Freyman, Y.
Magallanes, K.
Lanham, P.
Rathore, A.
Li, A.
Aubi, O.
Hughes, P. E.
Teriete, P.
White, M. A.
Neilan, C. L.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S84 - S84

← 1 2 3 4 5 →